A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM Patients
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 211 participants.
Also called NCT05680155
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 211 participants
- Sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
- Registry
-
NCT05680155
-
- Other papers using this trial's data
- Efficacy and safety of cAMP signalling-biased GLP-1 analogue ecnoglutide monotherapy versus placebo in patients with type 2 diabetes (EECOH-1): a multi-centre, randomised, double-blind, placebo-controlled, phase 3 trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT05680155. Randomized; double masking; primary purpose treatment. Start 2022-12-29 (actual); primary completion 2024-06-12 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Placebo in T2DM Patients
- Condition
- T2DM
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Ecnoglutide
- Intervention (Drug)
- Placebo
- Lead sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
Record details
- Record id
cardio:ct-nct05680155- Content hash
a9dc39cc6e035b70b2c0df7255156706e141c22e3494aa50fb25dd85ae7cc564